Pittenger & Anderson Inc’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Pittenger & Anderson Inc’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-9	Closed	-$2K	–	389
2016 Q3	$2K	Buy	+9	New	+$1.55K	﹤0.01%	356

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Pittenger & Anderson Inc's BLCM Position: Q4 2016 in Review

Pittenger & Anderson Inc sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2016, closing a stake of 9 shares — an estimated $2K sold.

Pittenger & Anderson Inc first reported a position in BLCM in Q3 2016 and held it in 1 quarter. The position peaked at $2K in Q3 2016. 80 funds tracked by Wall St. Rank hold BLCM as of Q4 2016.

Pittenger & Anderson Inc reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Pittenger & Anderson Inc sold 9 Bellicum Pharmaceuticals, Inc. shares in Q4 2016, an estimated $2K.
Pittenger & Anderson Inc first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
Pittenger & Anderson Inc's Bellicum Pharmaceuticals, Inc. position peaked at $2K in Q3 2016.
80 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2016.

Based on Pittenger & Anderson Inc's 13F filing for Q4 2016, filed 16 Feb 2017.